Travere Therapeutics (TVTX) In-Depth Analysis: The Current State of a Biotech Building on Rare Kidney Disease Drug “FILSPARI,” Expanding Indications and Establishing a Second Growth Pillar

* This report is based on data as of 2026-02-22.

1. First, what does this company do? (for middle schoolers)

Travere Therapeutics (TVTX) develops and sells drugs for rare diseases—conditions with small patient populations where treatment options are often limited. The company’s sweet spot is kidney disease: progressive conditions where, without effective treatment, patients can move steadily toward kidney failure, and where there’s clear clinical and economic value in therapies that slow progression.

Pharma doesn’t work like a consumer product you pick off a shelf. It runs through a system where physicians prescribe, insurers approve payment, and pharmacies dispense to patients. In practice, TVTX’s “customers” include not just patients, but also prescribing specialists, hospitals and pharmacies, and payers (the organizations that shape pricing and access).

How it makes money (revenue model)

• In the U.S., it sells its drug directly to generate revenue (product sales)
• Outside the U.S., it relies on partners, earning milestones and royalties from partner-led commercialization

Rare-disease drugs can be structurally durable businesses because even with small patient populations, once a therapy is embedded into standard-of-care, it often sees long duration of use. As “new starts” accumulate and “persistence” holds, the revenue base typically becomes more resilient.

Current flagship: “FILSPARI” for IgA nephropathy

Today, the biggest pillar is FILSPARI (generic name: sparsentan) for the rare kidney disease IgA nephropathy. IgA nephropathy involves inflammation in the kidneys and a gradual decline in function; as it progresses, the risk of dialysis or kidney transplant increases.

TVTX positions FILSPARI not as a short-term symptom suppressor, but as a foundational therapy aimed at long-term kidney protection. Commercial traction has been building as well: company disclosures show FY2025 U.S. FILSPARI net sales of approximately $322 million for the full year and approximately $103 million in 2025 Q4 (Oct–Dec).

Why it tends to be selected (value proposition)

• Long-term outcomes focus: straightforward to frame as “kidney protection,” i.e., slowing the decline in kidney function
• Fits naturally into specialist treatment algorithms: adoption can accelerate as its role as a foundational therapy becomes clearer
• Adoption improves as operational burden falls: real-world safety-management workload can be a meaningful source of friction

Key recent update: REMS requirements became lighter

FILSPARI previously carried a safety-management framework (REMS), but the U.S. FDA reduced liver function testing frequency from “monthly” to “every 3 months” and removed certain additional requirements. That lowers the burden on physicians and patients and reduces both the psychological and operational hurdles to starting therapy.

2. The growth map: what are the tailwinds, and what is the next pillar?

TVTX’s growth isn’t just about “having a good drug.” It depends heavily on whether the company can execute the real-world operating engine of initiation and persistence in rare-disease settings. With that context, the growth drivers break down into three broad buckets.

Growth driver #1: Build “new starts” and “persistence” in IgA nephropathy

Rare-disease drugs often spread within specialist communities through a familiar pattern: “try it → see results → continue → refer.” Company disclosures indicate that new patient start procedures have remained at high levels, supporting the view that demand remains intact.

Growth driver #2: Expand revenue sources via partner-led ex-U.S. commercialization

Outside the U.S., the strategy is to participate in value creation through partnerships rather than building a full in-house commercial infrastructure. Disclosures cite progress in a European launch via a partner (CSL Vifor) and note that a filing in Japan is expected on the partner side. Because this model blends product revenue with milestones and royalties, reported results can become harder to read—an important baseline assumption.

Growth driver #3: If label expansion (FSGS) is approved, it is “incremental upside on the same commercial base”

Expanding FILSPARI into another rare kidney disease, FSGS (focal segmental glomerulosclerosis), is a key lever that could materially improve commercial efficiency if successful. In company messaging, it’s framed as an area that “could become the first approved therapy.”

That said, the review timeline has moved. The action date was initially stated as January 13, 2026; the company later indicated the possibility of a delay tied to additional information submissions; and releases have since updated the action date to April 13, 2026. This is both a growth lever and directly connected to the “Invisible Fragility” discussed later.

Future pillar candidates: horizontal expansion of indications + a second pipeline

• References to studies (SPARX) targeting recurrent IgA nephropathy post-transplant and FSGS, creating potential for future label additions
• A development program for HCU (classical homocystinuria), pegtibatinase: positioned as a therapy that targets the disease closer to its root cause and aims to be “disease-modifying”

The HCU program previously paused Phase 3 enrollment to optimize commercial-scale manufacturing, and the latest update indicates it is targeting an enrollment restart in 2026 1Q. In other words, building a second pillar is not only about clinical execution—it also hinges on manufacturing and quality execution, which matters.

A middle-school analogy (only one)

TVTX is like a company that drives a restaurant’s success with its signature dish (FILSPARI in IgA nephropathy), adds more menu items using the same kitchen and staff (FSGS, etc.), and also builds a second location in a different category (HCU).

Important caveats as business prerequisites

• Whether and when approvals happen can be major business inflection points (more indications can drive growth, but events can also increase volatility)
• Safety-management requirements influence adoption (FILSPARI’s requirements have been simplified)
• Because ex-U.S. is partnership-based, company revenue and milestones/royalties can be blended, changing how the revenue profile appears

3. Long-term fundamentals: what is this company’s “type”?

In a Lynch-style classification using long-term numbers, the materials flag “Cyclicals” as true. That likely reflects less classic macro sensitivity (commodities, autos, etc.) and more a pattern where revenue and profit move in step-functions around approvals, launches, and label expansions—making results look “cycle-like” (something to cross-check against the short-term data discussed later).

Revenue is high-growth, but with step-changes

• 10-year revenue CAGR: +17.3%
• 5-year revenue CAGR: +19.9%
• FY revenue: $132 million in 2021 → $491 million in 2025

The long-term direction is up, but there were declines in some interim years, and the pattern looks more stepwise than linear.

Profitability and capital efficiency are unstable (ROE is mostly negative)

• ROE (FY2025): -22.3%
• TTM net income: -$48.42 million

FY ROE has been negative for an extended period, with some years showing extreme swings. Relative to revenue growth, profitability has not been stable, making it difficult—based on the materials—to view the company as a long-term “stable grower” or “high-quality grower.”

EPS and FCF are “difficult to evaluate as long-term CAGRs”

Because FY EPS moves between losses and profits, 5-year and 10-year EPS growth rates cannot be calculated (insufficient data / not a continuous series). FCF was also negative for many FY periods, then turned positive in FY2025 at +$37.78 million, but is similarly treated as difficult to evaluate as a long-term CAGR.

FY showed “narrowing losses + positive FCF,” but persistence in TTM cannot be fully confirmed

• Net income (FY): FY2024 -$322 million → FY2025 -$25.55 million
• FCF (FY): FY2024 -$339 million → FY2025 +$37.78 million
• Revenue (FY): FY2024 $233 million → FY2025 $491 million

Looking only at the FY sequence, it reads like a “rebound off the bottom.” However, because TTM FCF cannot be calculated, it’s still hard to confirm whether that improvement is holding on a TTM basis—an important caveat.

Long-term margins: significant improvement in FY2025

• Operating margin: FY2024 -138.9% → FY2025 -10.2%
• Net margin: FY2024 -137.9% → FY2025 -5.2%
• FCF margin: FY2024 -145.3% → FY2025 +7.7%

FY margins improved sharply, but as discussed later, TTM EPS remains weak. The fact that FY and TTM “tell different stories” reflects period differences and is something that needs additional validation.

Source of growth: dilution (share count increase) is also occurring

The materials show shares outstanding rising from 25.06 million in FY2014 → 89.21 million in FY2025. Revenue has grown, but with profitability negative for a long stretch, it’s difficult to explain EPS performance “just through revenue growth,” leading to the view that without margin normalization, it’s harder to frame the profile as “stable growth”.

Dividends and capital allocation: difficult to anchor as a dividend investment

Because the latest TTM dividend yield and dividend amount cannot be calculated (insufficient data), the current dividend policy can’t be stated definitively. Dividend history is also limited to 1 year of dividend payments. At least within the scope of the materials, this is not a stock to underwrite primarily on dividends; it’s framed instead around commercial execution, label expansion, and development progress as the core capital-allocation themes (share price on the report date: $30.39).

4. Short-term (TTM / last 8 quarters) momentum: is the long-term “type” being maintained?

This is central to the investment decision. In the near term, the profile is showing strong revenue momentum alongside weakening profit (EPS) momentum.

TTM snapshot: coexistence of surging revenue and worsening EPS

• Revenue (TTM): $491 million
• Revenue growth (TTM YoY): +110.5%
• EPS (TTM): -0.536
• EPS growth (TTM YoY): -86.1%
• FCF (TTM): Cannot be calculated (insufficient data)

The revenue ramp looks less like macro cyclicality and more like step-change growth driven by penetration and event dynamics. Meanwhile, EPS is negative and has worsened YoY. So while the Lynch flag reads “Cyclicals,” the materials highlight a mismatch: “economic cyclicality” alone doesn’t explain the pattern, and you need an additional lens around ramp-up and event-driven dynamics.

Momentum assessment: Decelerating

On revenue alone, TTM growth (+110.5%) is far above the 5-year FY average (+19.9%), which would suggest acceleration. But with TTM EPS growth clearly deteriorating at -86.1%, the combined short-term read across EPS, revenue, and FCF is categorized as Decelerating. And because FCF (TTM) cannot be calculated, there’s a practical limitation: you can’t confirm in the near term whether revenue growth is being supported by cash generation.

Short-term margin implication: the gap between FY improvement and TTM weakness

FY operating margin improved sharply from -138.9% to -10.2%, yet TTM EPS deteriorated. That leaves open the possibility that the FY improvement is not compounding cleanly into the TTM picture. This is a point that requires decomposition (for example, separating “one-time factors” from underlying cost structure).

5. Financial soundness (how to view bankruptcy risk): there is a cushion, but caution remains in weak-profit phases

TVTX has meaningful liquidity, but its capital structure and interest-coverage profile have some clear features.

• Cash ratio (FY2025): 2.02
• Debt-to-equity (FY2025): 2.86
• Net Debt / EBITDA (FY2025): 0.57x
• Interest coverage (FY2025): -4.68 (negative)

A high cash ratio suggests a near-term liquidity buffer. On the other hand, debt-to-equity is elevated and interest coverage is negative, so if weak profitability persists, debt-service capacity can become a constraint that matters more. The materials don’t argue for imminent distress; instead, they frame the setup as one where “P&L repair (whether profits actually follow revenue)” matters more than “financial slack”.

6. Current valuation positioning (company historical only): a mix of metrics you can and cannot anchor

Here, without peer or market comparisons, we’re simply placing “today” against TVTX’s own historical ranges (primarily the past 5 years, with the past 10 years as context). As a baseline, because TTM EPS is negative and TTM FCF cannot be calculated, several valuation metrics end up in a state where “the current value can’t be plotted.” That “unplottable” condition is itself part of the current setup.

PEG: difficult to evaluate both current value and historical distribution

With TTM EPS growth negative (-86.1%), PEG isn’t meaningful, and the materials treat it as difficult to evaluate in this period, including the historical distribution. In other words, PEG isn’t a usable axis right now.

P/E: there is a historical distribution, but the current value cannot be placed due to losses

Because TTM EPS is negative, the current P/E cannot be calculated. That said, P/E was meaningful in some historical periods; the past 5-year median is 6.36x, and the typical range (20–80%) is 6.09x to 7.71x. The current point, however, can’t be placed on that distribution.

Free cash flow yield: historically mostly negative; current value cannot be placed

Because TTM FCF cannot be calculated, current FCF yield is difficult to assess. The historical distribution shown is largely negative (past 5-year median -11.46%, past 10-year median -7.75%). The key point is that even if you can see the historical range, the current coordinate is missing.

ROE: improved to the “less negative” side within the historical distribution

ROE (FY2025) is -22.3%. Relative to the past 5-year median (-59.6%) and past 10-year median (-57.5%), it sits on the less negative side of the distribution. The materials note that within the past 5-year range it is above the typical-range upper bound (-48.8%), and within the past 10-year range it is near the upper bound (-21.9%). Over the last two years, ROE improved from FY2024 -544.3% → FY2025 -22.3%.

FCF margin: historically a deep negative distribution; current value cannot be placed

Because TTM FCF cannot be calculated, current FCF margin is difficult to evaluate. The historical distribution is centered in negative territory, with a past 5-year median of -145.3%, which is more negative than the past 10-year median (-35.8%) (i.e., the last 5 years reflect a harsher distribution).

Net Debt / EBITDA: a metric where the current value can be placed (though it moved upward over the last two years)

Net Debt / EBITDA is an inverse-style metric where smaller values (more negative) imply being closer to net cash and having more flexibility. FY2025 is 0.57x, within the past 5-year range (0.09x to 0.77x), and also within the typical range over the past 10 years, on the lower side versus the median (1.29x).

Over the last two years, FY2024 was -0.12x and FY2025 was 0.57x, meaning the metric has moved up from negative toward positive. This is not framed as good or bad—just the factual historical positioning.

7. How to read cash flow: consistency between EPS and FCF, and the “parts that cannot be confirmed”

TVTX generated positive FY FCF in FY2025 (+$37.78 million), but because TTM FCF cannot be calculated, it remains difficult to confirm whether cash generation has persisted over the most recent year. The materials are explicit about the limitation: quarterly TTM FCF is observed as of 25Q3 at -$80.33 million, but 25Q4 is missing, so continuity can’t be assessed on a TTM basis.

When “revenue is strong but EPS is weak,” investors naturally want to separate whether revenue growth reflects (1) temporary profit pressure from investment or (2) weaker-than-expected commercialization economics. But within the scope of the materials, because TTM FCF is missing, the delayed ability to validate the story through cash should be treated as a baseline constraint.

8. Why TVTX has been winning (the core of the success story)

TVTX’s underlying value proposition is its ability to implement, in real-world care, therapies that slow disease progression in progressive rare kidney diseases. Rare diseases may have small patient populations, but options are often limited; once a therapy becomes standard-of-care, persistence tends to be high.

The success formula here isn’t a complex, self-reinforcing platform. It’s relatively straightforward.

• Embed into specialist treatment algorithms (secure a defined role as a foundational therapy)
• Reduce friction in initiation and persistence (safety management, payer access, and operational execution)
• Expand indications through the same sites and initiation pathways (commercial leverage from label expansion)

In that context, REMS simplification is a concrete shift toward “easier to use,” reinforcing the penetration narrative.

9. Is the story still intact? (narrative consistency)

The main narrative change over the last ~1 to 1.5 years is less “the drug’s value changed” and more “the conditions of use improved”. Specifically, reduced REMS burden has become part of the story as a factor that lowers friction to starting therapy.

At the same time, IgA nephropathy is seeing more options and intensifying competition, which raises the bar on sustaining FILSPARI’s “foundational therapy” positioning in day-to-day practice. And FSGS—central to the forward narrative—is entering a phase where timeline visibility is getting worse, as reflected in the action-date extension (January 2026 → April 2026).

10. Invisible Fragility: 8 issues to stress-test most when things look strong

Rather than claiming “it’s already breaking,” this section organizes structural risks that matter most when things do break. In rare-disease biotech, as revenue ramps, fragilities can paradoxically become more visible.

1) It can effectively become a “single-flagship” company (concentration risk)

Near-term growth is heavily driven by FILSPARI, and the faster the ramp, the more a single-product issue can translate into a company-wide slowdown. In other words, concentration risk becomes more tangible because the business has scaled.

2) Rapid shifts in the competitive environment: differences in operational burden can drive share

If same-class competitors can credibly market lighter operational requirements (for example, “no REMS”), ease of initiation can influence prescribing when efficacy looks broadly comparable. TVTX has moved to simplify requirements, but operational burden can remain a competitive variable.

3) Relative differentiation: as options increase, the “standalone necessity” can weaken

In IgA nephropathy, more drugs with different mechanisms are emerging, and the treatment environment often shifts toward combinations, sequencing, and patient stratification. If the company can’t sustain a clear “why this drug for this patient” narrative, adoption could gradually slow.

4) Supply chain dependence: HCU has already shown manufacturing scale as a bottleneck

In the HCU program, enrollment was temporarily paused due to manufacturing optimization. As the pipeline broadens, manufacturing, quality, and vendor oversight can become “hard-to-see” sources of delay.

5) Organizational culture degradation: limited confirming evidence, but parallel-load structurally tends to rise

The materials note there isn’t enough primary evidence to conclude a “sharp deterioration in culture” from late 2025 to early 2026, and that definitive claims should be avoided. Still, running commercial expansion, label-expansion preparation, and a restart of a second pipeline at the same time increases operational load. Attrition, hiring friction, and slower execution can show up with a lag, making this a structural monitoring item.

6) Profitability deterioration: strong revenue and weak profits coexist

On a TTM basis, revenue is surging while EPS is negative and worsening YoY. That can be consistent with an investment phase, but if it persists, it raises questions about commercialization economics. The fragility is the slow-burn scenario where adoption rises, costs rise alongside it, and profits don’t keep up.

7) Financial burden (debt-service capacity): constraints can amplify when profits are weak

Negative interest coverage means that in periods when interest burden matters, the company may have less flexibility around R&D and commercial investment. Fundraising isn’t unusual in rare-disease biotech, but if weak profitability persists, it can indirectly pressure the growth narrative through reprioritization or deferrals.

8) Industry structure: even post-approval, additional data can still shift the narrative

In nephrology, programs may advance on surrogate endpoints, but confirmatory trials and incremental data are still required. The process of submitting additional information in the FSGS review underscores that label expansion is rarely a straight line.

11. Competitive landscape: who is it fighting, and how?

Competition for TVTX is shaped not only by drug performance, but also by approved indications, evidence, prescribing burden, payer access, and entrenchment within specialist communities. As options expand, patient-by-patient selection, combinations, and sequencing matter more, and the “must-use” status of any single agent tends to be diluted.

Key competitive players (primarily IgA nephropathy)

• Novartis: an IgA nephropathy drug targeting the endothelin pathway (Vanrafia/atrasentan). It can more easily emphasize a no-REMS position, making operational burden a potential point of differentiation.
• Otsuka (including assets originating from Visterra): expands options via APRIL inhibition (sibeprenlimab). Mechanistic differences in immunology could reshape patient selection.
• Vera Therapeutics: an immune-related mechanism (atacicept). It can drive not only substitution but also competition around combinations and sequencing.
• Supportive care / already-approved drugs: IgA nephropathy is often layered on top of RAS inhibition and SGLT2 inhibition, with disease-specific therapies added above that base.

Competitive focus by area

• IgA nephropathy: centered on proteinuria reduction and kidney protection, with attention on operational ease (REMS, etc.) within similar classes and algorithm shifts driven by the rise of immune mechanisms.
• FSGS: in the materials’ framing, discussed under the premise that “no approved drug exists,” so the key variables are less about share battles and more about approval outcome, conditions of use, additional trials, and timeline.
• HCU: positioned as an area where development, manufacturing, and execution (time, quality, supply) are likely to be the primary competitive dimensions.

Competitive KPIs investors should monitor (field-level variables)

• Whether new starts in IgA nephropathy remain durable
• The structure of persistence proxy indicators (reasons for discontinuation: adverse events, operational burden, payer access, switching to alternatives, etc.)
• Whether REMS simplification has been standardized at provider sites and reduced day-to-day workload
• Competitors’ updates on label expansions and confirmatory data (especially kidney function outcomes)
• Progress in FSGS (approval, conditions, need for additional trials) and timeline
• Whether specialist messaging is shifting toward “first-line / add-on / later-line” positioning

12. The nature and durability of the moat (competitive advantage)

TVTX’s moat isn’t a network effect like social media. It’s a “composite barrier” that matters in rare-disease clinical practice.

• Regulatory barriers: approved indications and labeling can create meaningful barriers
• Accumulation of clinical data: confirmatory trials and post-marketing experience build confidence
• Commercial execution in specialist channels: the ability to run initiation, testing workflows, and payer access is a practical barrier

That said, durability can be quickly relativized. As competition increases in IgA nephropathy, the moat shifts from “the only drug” to “execution, positioning, and cumulative data.” The materials also note that if competitors are perceived to have lighter operational burden within the same class, relative comparisons become more likely.

13. Structural positioning in the AI era: tailwind or headwind?

In the materials’ framing, TVTX is not a company where AI is the core value driver. But as AI adoption makes competition more measurable and comparative, the company sits in a landscape where relative evaluation can become more rigorous.

Summary across seven lenses

• Network effects: limited (adoption is driven mainly by evidence and specialist-community uptake)
• Data advantage: embedded in clinical, regulatory, and post-marketing operations, but limited evidence that it is a decisive proprietary data asset
• AI integration: likely additive as support (commercial operations, patient support, operational efficiency)
• Mission criticality: high clinically, but not in the sense of AI dependence
• Barriers to entry: medium to high via a mix of regulatory, clinical, manufacturing, and commercial execution, but increasingly relative as competitors emerge
• AI substitution risk: low for replacing drug efficacy, but better decision support could make weakly differentiated drugs less likely to be selected
• Layer position: application layer (the drug itself). AI is a supporting layer that can improve surrounding operations

As AI advances, what matters most isn’t AI functionality itself, but clinical evidence, usability (operational friction), and breadth of indications, where comparisons become more explicit. TVTX’s long-term path to winning remains concentrated in establishing FILSPARI as a foundational therapy in IgA nephropathy, reducing single-product dependence through FSGS and additional pipeline assets, and running access, persistence, and monitoring with minimal friction.

14. Management and culture: CEO consistency and the difficulty of a parallel-execution phase

CEO Eric Dube’s external messaging emphasizes “rare-disease patients do not have time,” patient-centricity, and speed—while maintaining safety. The business narrative is also delivered with a consistent through-line: entrench commercialization in IgA nephropathy → expand into FSGS → build a second pillar in HCU.

Profile (abstracted from public information)

• Vision: in rare diseases with limited options, aim to secure “a place within standard-of-care”
• Personality tendencies: goal- and speed-oriented; emphasizes not only R&D but also commercialization and implementation
• Values: patient-centricity, balancing safety and speed, execution focus
• Priorities: maintain FILSPARI penetration without disruption, prepare for an FSGS launch, and restart HCU Phase 3 in parallel (with manufacturing/quality complexity as a constraint)

A phase where culture is tested: commercialization × development in parallel

The materials state there isn’t enough evidence to conclude a sharp deterioration in organizational culture, while also noting that running commercial expansion alongside multiple development priorities raises the importance of prioritization and execution management—and that burnout and attrition can surface with a lag. For long-term investors, mission clarity can be a positive, but how management defines and executes the line between “investing for growth” and “cost discipline” becomes increasingly important.

Generalized patterns in employee reviews (no quotations)

• More likely to be positive: mission significance, flexibility, highly specialized environment
• More likely to be negative: uneven management quality, unclear career paths, dissatisfaction with workload/processes/evaluation

15. Understanding via a KPI tree: the causal structure that determines enterprise value

To evaluate TVTX as a set of drivers rather than a narrative, translating the materials’ KPI tree into investor terms, what ultimately matters is durable profitability, cash generation, capital efficiency, financial durability, and reduced dependence on a single product.

Intermediate KPIs (value drivers)

• Revenue growth: new starts × persistence (the core engine in rare disease)
• Profitability improvement: revenue growth doesn’t automatically translate into profits if SG&A, R&D, and operating costs rise in parallel
• Quality of cash conversion: payment terms, access support, and distribution design can influence cash inflows and outflows
• Lower operational friction: adoption typically improves as safety management, testing, and administrative burden decline
• Label expansion: whether incremental revenue can be added on the same commercial base
• Progress on the second pillar: whether HCU development, manufacturing, and execution advance
• Maintaining positioning under competition: whether the “why this drug for this patient” narrative stays compelling

Bottleneck hypotheses (what investors should monitor consistently)

• How quickly revenue growth translates into profits (loss narrowing to profitability)
• Whether TTM FCF becomes available and revenue growth is validated by cash generation
• Whether both wheels—new starts and persistence—hold (either one breaking can destabilize the base)
• Whether REMS simplification becomes standardized in practice and initiation friction actually declines
• Whether positioning is drifting under competitive pressure
• Whether FSGS timeline shifts are creating distortions in organizational load or cost structure
• Whether manufacturing/quality bottlenecks in HCU recur
• Whether parallel execution load is becoming excessive and slowing execution speed
• Whether interest-coverage capacity or leverage is increasingly constraining continued investment

16. Two-minute Drill (the core of the TVTX investment thesis in 2 minutes)

TVTX is working to commercialize FILSPARI in the U.S. by embedding it into standard workflows in rare kidney disease, while building additional pillars through a potential label expansion into FSGS and a second pipeline program in HCU. Revenue is strong at $491 million TTM, up +110.5% YoY, while EPS is -0.536 TTM and has deteriorated YoY; short-term momentum is categorized as Decelerating.

Longer term, FY2025 shows improvement—narrowing losses and positive FCF—but because TTM FCF cannot be calculated, the key limitation is that near-term cash generation can’t be used to validate the trend. In IgA nephropathy, the competitive set is expanding, and differentiation is likely to be determined not only by efficacy but also by operational burden (safety management) and a defined role in the treatment algorithm. Lighter REMS requirements can be a tailwind, but the company also carries “Invisible Fragility” risks, including reliance on a single flagship, the FSGS timeline, manufacturing execution in HCU, and interest-coverage capacity.

For long-term investors, the crux is whether the flywheel of new starts and persistence remains intact, whether label expansion creates leverage on the existing commercial base, and—most importantly—whether revenue growth ultimately converts into profit and cash. This is a story where progress is measured less by narrative and more by execution and accumulation.